Forensic Analysis · Healthcare / Pharmaceuticals / Biotech · as of Jun 27, 2026
Celcuity Inc. (CELC)
A forensic read on Celcuity Inc. built from its complete SEC filings — financial-health screens, earnings quality, red flags and a price-aware rating. Reproducible math, not opinion.
D · Weak — demands caution
Forensic grade
Clean
Earnings quality
2
Forensic signals
-244.6%
ROE
$4.9B
Market cap
Celcuity Inc. earns a D (Weak — demands caution) forensic quality grade. 2 forensic signals were flagged in its latest SEC filings, led by return on invested capital.
What the filings flag
-53%Return on invested capital. Return on invested capital is -53% and slipping from -22% — well below its ~10% cost of capital, so reinvested dollars may be destroying value, not building it.
+67.8%/yrShare-count dilution. Diluted share count changed +203% over the last 3 years to FY2025 (+67.8%/yr). The count is GROWING — existing holders are being diluted. That's ~67.8% shaved off per-share growth every year — total profit has to grow that much just to keep earnings-per-share flat, and a stake held since FY2022 has been diluted ~203%.
Key fundamentals
Debt / Equity1.37x
Free Cash Flow$-153.5M
Return on Equity-176.1%
Go deeper — free with an account
The forensic grade and screens above are free — no account needed. An account adds the full interactive deep-dive on Celcuity Inc.:
🔒The written investment read — what the numbers mean, in plain English
🔒Ask anything about CELC's filings — AI Q&A across the 10-K, 10-Qs & 8-Ks
🔒Interactive valuation — reverse-DCF sliders, Monte Carlo & scenario stress
🔒Calibrated 12-month price forecast, with the math shown
🔒Peer comparison + filing-change monitoring & alerts
No credit card · informational only, not investment advice · see the track record
← Browse all forensic stock analyses
Data from SEC EDGAR public filings · metrics as of Jun 27, 2026. Forensic signals flag probability, not certainty.